Spasticity in Spinal Cord Injured Persons Clinical Trial
Official title:
Randomized Double Blind Cross Over Study Assessing the Effect of Cannabiniods on Spasticity in Spinal Cord Injured Persons :A Pilot Study
| Verified date | June 2007 |
| Source | University of Manitoba |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Canada: Health Canada |
| Study type | Interventional |
Objectives: To determine whether nabilone, a synthetic cannabinoid, alleviates spasticity in
people with spinal cord injury (SCI).
Methods: Twelve subjects were enrolled in this double-blind, placebo-controlled, crossover
study. They received either nabilone or placebo during the first four-week period (0.5mg OD
with option to increase to 0.5mg BID), then outcome measures were assessed. After a two-week
washout, subjects were crossed-over to the opposite arm.
The primary outcome was the Ashworth scale for spasticity in the most involved muscle group,
chosen by the subject and clinician. The secondary outcomes included Spasm Frequency Scale,
Visual Analog Scale, Wartenberg Pendulum Test, sum of the Ashworth Scale in eight muscle
groups of each side of the body, and the Clinician's and Subject's Global Impression of
Change .
| Status | Completed |
| Enrollment | 0 |
| Est. completion date | December 2007 |
| Est. primary completion date | November 2007 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Patients with spinal cord injury were eligible for the study if they are 18-65 years old, have C5 (ASIA A-D) and below and the injury occurred greater than 1 year previously. They had to have stable neurological level of injury with moderate spasticity (Ashworth >/= 3) and no cognitive impairments. The spasticity medications needed to be unchanged for at least 30 days before inclusion, and no botulinum toxin injections for > 4 months. Exclusion Criteria: They were excluded if they had: - Heart disease as cannabinoids can reduce heart rate and blood pressure - History of psychotic disorders, schizophrenia or any active psychological disorder - Previously documented sensitivity to marijuana or other cannabinoid agents - Severe liver dysfunction - Cognitive impairment - Major illness in another body area - If they were pregnant or nursing mother - Had history of drug dependency - Used smoked cannabis < 30 days before the onset of the study or were unwilling not to smoke during the study; OR - If they fixed tendon contractures |
N/A
| Country | Name | City | State |
|---|---|---|---|
| Canada | Rehabilitation hospital ,800 sherbrook St. | Winnipeg | Manitoba |
| Lead Sponsor | Collaborator |
|---|---|
| University of Manitoba | Valeant Canada Limited |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Ashworth scale in most involved group muscles | 10 weeks | Yes | |
| Secondary | The secondary outcomes included Spasm Frequency Scale, Visual Analog Scale, Wartenberg Pendulum Test, sum of the Ashworth Scale in eight muscle groups of each side of the body, and the Clinician's and Subject's Global Impression of Change . | 10 weeks | Yes |